Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)

• Published in: European heart journal Vol. 36; no. 27; pp. 1744 - 1753
• Main Authors: Mathiasen, Anders Bruun, Qayyum, Abbas Ali, Jørgensen, Erik, Helqvist, Steffen, Fischer-Nielsen, Anne, Kofoed, Klaus F, Haack-Sørensen, Mandana, Ekblond, Annette, Kastrup, Jens
• Format: Journal Article
• Language: English
• Published: England 14.07.2015
• Subjects: Adult; Aged; Aged, 80 and over; Cardiac Imaging Techniques - methods; Double-Blind Method; Female; Heart Failure - therapy; Humans; Injections, Intralesional; Magnetic Resonance Angiography; Male; Mesenchymal Stem Cell Transplantation - methods; Middle Aged; Myocardial Ischemia - therapy; Quality of Life; Tomography, X-Ray Computed; Heart failure; Clinical trial; Mesenchymal stromal cell; Ischaemic heart disease; Stem cell
• ISSN: 0195-668X; 1522-9645
• DOI: 10.1093/eurheartj/ehv136

Regenerative treatment with mesenchymal stromal cells (MSCs) has been promising in patients with ischaemic heart failure but needs confirmation in larger randomized trials. We aimed to study effects of intra-myocardial autologous bone marrow-derived MSC treatment in patients with severe ischaemic heart failure. The MSC-HF trial is a randomized, double-blind, placebo-controlled trial. Patients were randomized 2 : 1 to intra-myocardial injections of MSC or placebo, respectively. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography at 6 months follow-up. Sixty patients aged 30-80 years with severe ischaemic heart failure, New York Heart Association (NYHA) classes II-III, left ventricular ejection fraction (LVEF) <45% and no further treatment options were randomized. Fifty-five patients completed the 6-month follow-up (37 MSCs vs. 18 placebo). At 6 months, LVESV was reduced in the MSC group: -7.6 (95% CI -11.8 to -3.4) mL (P = 0.001), and increased in the placebo group: 5.4 (95% CI -0.4 to 11.2) mL (P = 0.07). The difference between groups was 13.0 (95% CI 5.9-20.1) mL (P = 0.001). Compared with placebo, there were also significant improvements in LVEF of 6.2% (P<0.0001), stroke volume of 18.4 mL (P < 0.0001), and myocardial mass of 5.7 g (P = 0.001). No differences were found in NYHA class, 6-min walking test and Kansas City cardiomyopathy questionnaire. No side effects were identified. Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure. NCT00644410 (ClinicalTrials.gov).